A Phase IIa trial of Galinpepimut-S in Acute myeloid leukemia
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2018
Price : $35 *
At a glance
- Drugs Galinpepimut S (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2018 New trial record
- 28 Nov 2018 According to the Sellas Life Sciences Group media release, this trial was conducted at the Moffitt Cancer Center, USA.
- 28 Nov 2018 Results presented in the Sellas Life Sciences Group media release.